STOCK TITAN
  1. Home
  2. News
  3. CNTG

Centogene N.V. Common Shares - CNTG STOCK NEWS

Welcome to our dedicated page for Centogene N.V. Common Shares news (Ticker: CNTG), a resource for investors and traders seeking the latest updates and insights on Centogene N.V. Common Shares stock.

Centogene N.V. (symbol: CNTG) is a leading global company in the field of genetic diagnostic testing for rare hereditary diseases. With an expansive test portfolio covering over 2,800 genes, as well as biochemical and biomarker tests, the company offers unparalleled expertise in whole exome sequencing and whole genome sequencing. Centogene's mission is to provide data-driven, life-changing answers to patients, physicians, and pharmaceutical companies by diagnosing the root causes of symptoms early on.

Centogene leverages its unique CentoMD® mutation database, integrating genetic and clinical information to deliver the highest quality genetic testing and biomarker development. This extensive database allows the company to maintain the largest systematic documentation of genetic results worldwide.

Beyond individual diagnostic services, Centogene is a pivotal partner for pharmaceutical companies, offering essential services such as early patient recruitment, epidemiological insights, biomarker discovery, and patient monitoring. The company operates in two main segments: pharmaceutical and diagnostics, serving regions including Europe, the Middle East, North America, and Latin America.

Recent achievements include the launch of innovative genomic and multiomic products, a significant joint venture in Saudi Arabia, and expanded collaborations with long-standing and new pharma partners. Despite the challenges posed by current financial markets, Centogene remains committed to growth and profitability, exploring strategic alternatives to unlock value for its stakeholders.

With ISO, CAP, and CLIA certified multiomic reference laboratories in Germany, Centogene's research and development efforts have led to over 285 peer-reviewed publications. The company's pioneering work in rare and neurodegenerative diseases has fostered collaborations with over 50 pharmaceutical partners, accelerating drug discovery and development.

To discover more about Centogene's products, pipeline, and patient-driven purpose, visit their website and follow them on LinkedIn.

News

CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders

Rhea-AI Summary
Centogene N.V. extends partnership with Takeda to provide efficient diagnosis for Lysosomal Storage Disorders globally, emphasizing rapid and reliable diagnostics for diseases like Fabry disease, Gaucher disease, and Hunter syndrome.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
partnership
-
News

CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα Deficiency

Rhea-AI Summary
CENTOGENE N.V. announces rare findings on pre-TCRα deficiency, highlighting the prevalence of partial forms over complete deficiency. The study sheds light on the impact on human immunity and potential noncanonical pathways for T cell development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
none
-
News

CENTOGENE Explores Strategic Alternatives

Rhea-AI Summary
Centogene N.V. (CNTG) announces exploration of strategic alternatives to enhance long-term value creation. The company aims to leverage its position as a world leader in rare disease diagnostics and pharma services. Management and the Supervisory Board are collaborating to evaluate options for sustainable growth and profitability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
none
News

CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing

Rhea-AI Summary
Centogene N.V. (CNTG) received a staff determination letter from Nasdaq regarding potential delisting due to non-compliance with the minimum USD $15 million Market Value of Publicly Held Shares requirement. However, this will not immediately result in the suspension or delisting of the company's securities. The company plans to request a hearing before a Hearings Panel to address the issue.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
none
-
News

CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration

Rhea-AI Summary
CENTOGENE N.V. (CNTG) and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine have announced a strategic research collaboration to accelerate and de-risk drug discovery and clinical development for rare disease patients. The collaboration aims to leverage the CENTOGENE Biodatabank, containing over 70 million unique genetic variants collected from more than 800,000 patients from over 120 countries, to discover and validate novel genetic and biochemical targets for future development of rare disease therapies. The partnership will integrate multiomics and bioinformatics to analyze the diverse data and improve patient health outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.5%
Tags
none
-
News

CENTOGENE Receives French Research Tax Credit Accreditation

Rhea-AI Summary
Centogene N.V. (CNTG) has been recognized by the French Ministry of Higher Education and Research as a qualified organization to support partners conducting R&D projects in France, enabling eligible research-based companies to claim tax relief on 30% of all costs incurred in R&D activities outsourced to CENTOGENE. This accreditation will lower overall R&D costs and support current and future partners in generating novel insights and delivering data-driven, life-changing answers to rare and neurodegenerative disease patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4%
Tags
none
News

CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using Multiomics

Rhea-AI Summary
Centogene N.V. (Nasdaq: CNTG) and The Michael J. Fox Foundation for Parkinson’s Research (MJFF) have announced a collaboration to accelerate research on genetic risk factors associated with Parkinson’s disease (PD), specifically targeting the role of variants in the GBA gene. The aim is to establish a deeper understanding of the relationship between specific GBA gene variants and PD, leveraging CENTOGENE’s expertise in rare genetic and neurodegenerative diseases and MJFF’s extensive expertise and resources. PD is a devastating neurodegenerative disease affecting over 10 million people worldwide, with many cases being linked to genetic factors. The research project will draw on diverse multiomic data in the CENTOGENE Biodatabank, which currently contains more than 800,000 patients representing over 120 highly diverse countries, including over 15,000 Parkinson’s disease datasets from the Company’s ROPAD Study, the world’s largest observational study on PD genetics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

CENTOGENE Announces Preliminary Full Year 2023 Revenue

Rhea-AI Summary
Centogene N.V. (Nasdaq: CNTG) announced preliminary unaudited revenue for full year 2023 between approximately €48.5 million and €49.0 million, reflecting a growth rate over 2022 in the mid-single digits. They strengthened their diagnostic portfolio, launched additional data and wet lab solutions, and expanded their partnership model with a new joint venture in Saudi Arabia. However, they experienced a lag in Pharma program timelines, impacting their full year 2023 Pharma segment revenue. Heading into 2024, their Pharma order book is set to hit new record levels, with extended relationships with existing biopharma partners and collaborations with 10 new partners.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
none
-
News

CENTOGENE Announces Voting Results of Extraordinary General Meeting

Rhea-AI Summary
Centogene N.V. (Nasdaq: CNTG) announced the voting results of the Company’s Extraordinary General Meeting, including the adoption of Dutch statutory annual accounts for the financial year ended December 31, 2022, all passed by the requisite majority.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.31%
Tags
none
News

CENTOGENE’s Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone

Rhea-AI Summary
Centogene N.V. (Nasdaq: CNTG) has achieved its initial recruitment and genetic testing milestone in the EFRONT Study, aimed at advancing the genetic understanding of frontotemporal dementia (FTD). The study is conducted with support from Alector, a clinical-stage biotechnology company. CENTOGENE will continue to work with its network of physicians to enroll patients in the study under its Cento-FTD Program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
none

FAQ

What is the current stock price of Centogene N.V. Common Shares (CNTG)?

The current stock price of Centogene N.V. Common Shares (CNTG) is $0.5194 as of August 8, 2024.

What is the market cap of Centogene N.V. Common Shares (CNTG)?

The market cap of Centogene N.V. Common Shares (CNTG) is approximately 9.4M.

What does Centogene N.V. specialize in?

Centogene N.V. specializes in genetic diagnostic testing for rare hereditary diseases and offers a broad portfolio of genetic, biochemical, and biomarker tests.

What is CentoMD®?

CentoMD® is Centogene's mutation database that integrates genetic and clinical information, enabling high-quality genetic testing and biomarker development.

Which segments does Centogene operate in?

Centogene operates in two segments: pharmaceutical and diagnostics.

What regions does Centogene serve?

Centogene serves Europe, the Middle East, North America, and Latin America.

Who are Centogene’s main partners?

Centogene partners with leading pharmaceutical companies for services such as patient recruitment, biomarker discovery, and patient monitoring.

What are some recent achievements of Centogene?

Recent achievements include launching innovative genomic products, forming a joint venture in Saudi Arabia, and expanding pharma collaborations.

How does Centogene contribute to drug discovery?

Centogene accelerates drug discovery through partnerships with pharmaceutical companies, leveraging their extensive genetic data and multiomic technologies.

What research certifications does Centogene hold?

Centogene holds ISO, CAP, and CLIA certifications for their multiomic reference laboratories in Germany.

How extensive is Centogene's physician network?

Centogene has built a network of approximately 30,000 active physicians since its founding in 2006.

Where can I learn more about Centogene?

You can learn more about Centogene by visiting their website at www.centogene.com and following them on LinkedIn.

Stock CNTG logo
Centogene N.V. Common Shares

Nasdaq:CNTG

CNTG Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

CNTG Stock Data

9.43M
29.00M
4.57%
66.89%
0.28%
Diagnostics & Research
Healthcare
Link
United States of America
Rostock